Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

Separation of blood microsamples by exploiting sedimentation at the microscale.

Forchelet D, Béguin S, Sajic T, Bararpour N, Pataky Z, Frias M, Grabherr S, Augsburger M, Liu Y, Charnley M, Déglon J, Aebersold R, Thomas A, Renaud P.

Sci Rep. 2018 Sep 20;8(1):14101. doi: 10.1038/s41598-018-32314-4.

2.

The surface tells it all: relationship between volume and surface fraction of liquid dispersions.

Forel E, Rio E, Schneider M, Beguin S, Weaire D, Hutzler S, Drenckhan W.

Soft Matter. 2016 Sep 28;12(38):8025-8029.

PMID:
27714354
3.

Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).

Cuisset T, Grosdidier C, Loundou AD, Quilici J, Loosveld M, Camoin L, Pankert M, Beguin S, Lambert M, Morange PE, Bonnet JL, Alessi MC.

JACC Cardiovasc Interv. 2013 Aug;6(8):854-63. doi: 10.1016/j.jcin.2013.04.009.

4.

Water vapour and heat combine to elicit biting and biting persistence in tsetse.

Chappuis CJ, Béguin S, Vlimant M, Guerin PM.

Parasit Vectors. 2013 Aug 19;6(1):240. doi: 10.1186/1756-3305-6-240.

5.

Effectiveness of switching 'hyper responders' from Prasugrel to Clopidogrel after acute coronary syndrome: the POBA (Predictor of Bleeding with Antiplatelet drugs) SWITCH study.

Deharo P, Pons C, Pankert M, Bonnet G, Quilici J, Grosdidier C, Beguin S, Morange P, Alessi MC, Bonnet JL, Cuisset T.

Int J Cardiol. 2013 Oct 12;168(5):5004-5. doi: 10.1016/j.ijcard.2013.07.121. Epub 2013 Jul 31. No abstract available.

PMID:
23915522
6.

Off-label use of prasugrel in stable coronary artery disease is associated with greater degree of platelet inhibition compared with use after acute coronary syndrome.

Cuisset T, Cayla G, Quilici J, Pankert M, Deharo P, Bonnet G, Grosdidier C, Beguin S, Morange P, Bonnet JL, Alessi MC.

Int J Cardiol. 2013 Oct 3;168(3):2988-9. doi: 10.1016/j.ijcard.2013.04.052. Epub 2013 Apr 30. No abstract available.

PMID:
23642612
7.

Effect of motivational mobile phone short message service on aspirin adherence after coronary stenting for acute coronary syndrome.

Quilici J, Fugon L, Beguin S, Morange PE, Bonnet JL, Alessi MC, Carrieri P, Cuisset T.

Int J Cardiol. 2013 Sep 20;168(1):568-9. doi: 10.1016/j.ijcard.2013.01.252. Epub 2013 Feb 22. No abstract available.

PMID:
23462636
8.

Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications.

Grosdidier C, Quilici J, Loosveld M, Camoin L, Moro PJ, Saut N, Gaborit B, Pankert M, Cohen W, Lambert M, Beguin S, Morange PE, Bonnet JL, Alessi MC, Cuisset T.

Am J Cardiol. 2013 Apr 1;111(7):985-90. doi: 10.1016/j.amjcard.2012.12.013. Epub 2013 Jan 19.

PMID:
23340030
9.

Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: a rebuttal.

Hemker HC, Béguin S.

J Thromb Haemost. 2013 Mar;11(3):564. doi: 10.1111/jth.12116. No abstract available.

10.

CYP2C19*2 and *17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome.

Cuisset T, Loosveld M, Morange PE, Quilici J, Moro PJ, Saut N, Gaborit B, Castelli C, Beguin S, Grosdidier C, Fourcade L, Bonnet JL, Alessi MC.

JACC Cardiovasc Interv. 2012 Dec;5(12):1280-7. doi: 10.1016/j.jcin.2012.07.015.

11.

Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy.

Cuisset T, Gaborit B, Dubois N, Quilici J, Loosveld M, Beguin S, Loundou AD, Moro PJ, Morange PE, Alessi MC, Dutour A, Bonnet JL.

Int J Cardiol. 2013 Sep 20;168(1):523-8. doi: 10.1016/j.ijcard.2012.09.214. Epub 2012 Oct 16.

PMID:
23084816
12.

An epilepsy-related ARX polyalanine expansion modifies glutamatergic neurons excitability and morphology without affecting GABAergic neurons development.

Beguin S, Crépel V, Aniksztejn L, Becq H, Pelosi B, Pallesi-Pocachard E, Bouamrane L, Pasqualetti M, Kitamura K, Cardoso C, Represa A.

Cereb Cortex. 2013 Jun;23(6):1484-94. doi: 10.1093/cercor/bhs138. Epub 2012 May 24.

PMID:
22628459
13.

Cell-autonomous and cell-to-cell signalling events in normal and altered neuronal migration.

Manent JB, Beguin S, Ganay T, Represa A.

Eur J Neurosci. 2011 Nov;34(10):1595-608. doi: 10.1111/j.1460-9568.2011.07867.x. Review.

PMID:
22103417
14.

A glial origin for periventricular nodular heterotopia caused by impaired expression of Filamin-A.

Carabalona A, Beguin S, Pallesi-Pocachard E, Buhler E, Pellegrino C, Arnaud K, Hubert P, Oualha M, Siffroi JP, Khantane S, Coupry I, Goizet C, Gelot AB, Represa A, Cardoso C.

Hum Mol Genet. 2012 Mar 1;21(5):1004-17. doi: 10.1093/hmg/ddr531. Epub 2011 Nov 10.

PMID:
22076441
15.

Thrombin-generating capacity in patients with von Willebrand's disease.

Rugeri L, Beguin S, Hemker C, Bordet JC, Fleury R, Chatard B, Negrier C, Dargaud Y.

Haematologica. 2007 Dec;92(12):1639-46.

16.

Linear diffusion of thrombin and factor Xa along the heparin molecule explains the effects of extended heparin chain lengths.

Wagenvoord R, Al Dieri R, van Dedem G, Béguin S, Hemker HC.

Thromb Res. 2008;122(2):237-45. Epub 2007 Nov 28.

PMID:
18045667
17.

Thrombin generation, a function test of the haemostatic-thrombotic system.

Hemker HC, Al Dieri R, De Smedt E, Béguin S.

Thromb Haemost. 2006 Nov;96(5):553-61. Review.

PMID:
17080210
18.

Protocols for optimizing MS/MS parameters with an ion-trap GC-MS instrument.

Béguin S, Jadas-Hécart A, Tabet JC, Communal PY.

J Mass Spectrom. 2006 Oct;41(10):1304-14.

PMID:
17013828
19.

Low molecular weight activated protein C inhibitors as a potential treatment for hemophilic disorders.

De Nanteuil G, Gloanec P, Béguin S, Giesen PL, Hemker HC, Mennecier P, Rupin A, Verbeuren TJ.

J Med Chem. 2006 Aug 24;49(17):5047-50.

PMID:
16913694
20.

New approaches for measuring coagulation.

Barrowcliffe TW, Cattaneo M, Podda GM, Bucciarelli P, Lussana F, Lecchi A, Toh CH, Hemker HC, Béguin S, Ingerslev J, Sørensen B.

Haemophilia. 2006 Jul;12 Suppl 3:76-81. Review.

PMID:
16684000
21.
22.

Laboratory monitoring of low-molecular-weight heparin therapy--part II. Monitoring LMWH therapy? For the moment a non-question.

Hemker HC, Al Dieri R, Béguin S.

J Thromb Haemost. 2005 Mar;3(3):571-3. No abstract available.

23.

Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B.

Dargaud Y, Béguin S, Lienhart A, Al Dieri R, Trzeciak C, Bordet JC, Hemker HC, Negrier C.

Thromb Haemost. 2005 Mar;93(3):475-80.

PMID:
15735797
24.

Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time.

al Dieri R, Alban S, Béguin S, Hemker HC.

J Thromb Haemost. 2004 Aug;2(8):1395-401.

25.

Thrombin generation assays: accruing clinical relevance.

Hemker HC, Al Dieri R, Béguin S.

Curr Opin Hematol. 2004 May;11(3):170-5. Review.

PMID:
15257016
26.

Factor XI-dependent reciprocal thrombin generation consolidates blood coagulation when tissue factor is not available.

Wielders SJ, Béguin S, Hemker HC, Lindhout T.

Arterioscler Thromb Vasc Biol. 2004 Jun;24(6):1138-42. Epub 2004 Apr 8.

PMID:
15072993
27.

The love of the artist for his model of thrombin generation.

Hemker HC, Béguin S.

J Thromb Haemost. 2004 Mar;2(3):400-1. No abstract available.

28.
29.

Thrombin generation: old wine into new wineskins.

Coenraad Hemker H, Béguin S.

Thromb Haemost. 2003 Nov;90(5):764-5. No abstract available.

PMID:
14597965
30.

[The Choay domain -- the structure responsible for the anticoagulant action of heparins].

Hemker HC, al Dieri R, Wagenvoord R, Béguin S.

Bull Acad Natl Med. 2003;187(1):59-66; discussion 66-7. French.

PMID:
14556454
31.

The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability.

Hemker HC, Giesen P, AlDieri R, Regnault V, de Smed E, Wagenvoord R, Lecompte T, Béguin S.

Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):249-53. Review.

32.
33.

The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif--the C-domain.

Al Dieri R, Wagenvoord R, van Dedem GW, Béguin S, Hemker HC.

J Thromb Haemost. 2003 May;1(5):907-14.

34.

Calibrated automated thrombin generation in frozen-thawed platelet-rich plasma to detect hypercoagulability.

Regnault V, Béguin S, Lecompte T.

Pathophysiol Haemost Thromb. 2003;33(1):23-9.

35.

Calibrated automated thrombin generation measurement in clotting plasma.

Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Béguin S.

Pathophysiol Haemost Thromb. 2003;33(1):4-15.

36.

Thrombinography shows acquired resistance to activated protein C in patients with lupus anticoagulants.

Regnault V, Béguin S, Wahl D, de Maistre E, Coenraad Hemker H, Lecompte T.

Thromb Haemost. 2003 Feb;89(2):208-12.

PMID:
12574797
37.

The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding.

Al Dieri R, Peyvandi F, Santagostino E, Giansily M, Mannucci PM, Schved JF, Béguin S, Hemker HC.

Thromb Haemost. 2002 Oct;88(4):576-82.

PMID:
12362226
38.

Vitamin K-dependent and vitamin K-independent hypocoagulant effects of dietary fish oil in rats.

Nieuwenhuys CM, Feijge MA, Vermeer C, Hennissen AH, Béguin S, Heemskerk JW.

Thromb Res. 2001 Oct 15;104(2):137-47.

PMID:
11672757
39.

The role of factor XI in thrombin generation induced by low concentrations of tissue factor.

Keularts IM, Zivelin A, Seligsohn U, Hemker HC, Béguin S.

Thromb Haemost. 2001 Jun;85(6):1060-5.

PMID:
11434685
40.

An ionic contrast agent inhibits platelet-dependent thrombin generation and boosts the effect of abciximab.

Al Dieri R, de Muinck E, Hemker HC, Béguin S.

Thromb Haemost. 2001 May;85(5):944-5. No abstract available.

PMID:
11372697
41.

Monitoring hypocoagulant conditions in rat plasma: factors determining the endogenous thrombin potential of tissue factor-activated plasma.

Nieuwenhuys CM, Feijge MA, Béguin S, Heemskerk JW.

Thromb Haemost. 2000 Dec;84(6):1045-51.

PMID:
11154112
42.

Phenotyping the clotting system.

Hemker HC, Béguin S.

Thromb Haemost. 2000 Nov;84(5):747-51. Review. No abstract available.

PMID:
11127849
44.
46.

Basic residues of human group IIA phospholipase A2 are important for binding to factor Xa and prothrombinase inhibition comparison with other mammalian secreted phospholipases A2.

Mounier CM, Luchetta P, Lecut C, Koduri RS, Faure G, Lambeau G, Valentin E, Singer A, Ghomashchi F, Béguin S, Gelb MH, Bon C.

Eur J Biochem. 2000 Aug;267(16):4960-9.

47.

The thrombogram: monitoring thrombin generation in platelet-rich plasma.

Hemker HC, Giesen PL, Ramjee M, Wagenvoord R, Béguin S.

Thromb Haemost. 2000 Apr;83(4):589-91.

PMID:
10780322
49.

Draculin, the anticoagulant factor in vampire bat saliva, is a tight-binding, noncompetitive inhibitor of activated factor X.

Fernandez AZ, Tablante A, Beguín S, Hemker HC, Apitz-Castro R.

Biochim Biophys Acta. 1999 Sep 14;1434(1):135-42.

PMID:
10556567
50.

On the coagulation of platelet-rich plasma. Physiological mechanism and pharmacological consequences.

Béguin S, Keularts I.

Haemostasis. 1999 Sep;29(1):50-7. Review.

PMID:
10494034

Supplemental Content

Loading ...
Support Center